Skip to content
Screener

Wave Life Sciences WVE Total Non-Current Liabilities

Total Non-Current Liabilities at other companies

Eli Lilly logo
Eli LillyLLY
$60.66B+39.3%
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
$346.72M+182%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$17.92M-11.1%

Other financials

Income statement

See full
Revenue$2.3M-73.9%
Operating income-$73.8M-39.9%
Net income-$69.4M-37.4%
EPS (diluted)-$0.34-9.7%

Balance sheet

See full
Cash & equivalents$368.0M+76.5%
Total debt$43.6M+101%
Total equity$453.5M+226%
Total assets$558.3M+121%

Cash flow

See full
Operating cash flow-$53.6M-16.5%
CapEx$884.0K+189%
Free cash flow-$54.5M-17.6%

Valuation

See full
Market cap$1.2B-7.3%
Enterprise value$871.66M-21.0%
P/S20.5×-16.6×

Profitability

See full
Operating margin-75.7%-33.6pp
Net margin-66.5%-29.9pp
FCF margin-27.2%-12.6pp

Returns & leverage

See full
Return on equity-68.3%
Debt / equity0.1×-0.1×
Current ratio10×+7.4×

Where this comes from

Reported directly by Wave Life Sciences in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesNoncurrent.

The source filing: Wave Life Sciences’s 10-Q, filed July 30, 2026.

Filed
Jul 30, 2026, 7:50 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324949
Line itemJune 30, 2026December 31, 2025
Long-term liabilities:
Deferred revenue, net of current portion13,9047,798
Operating lease liability, net of current portion40,0829,405
Total long-term liabilities53,98617,203
Total liabilities$104,801$112,268
Series A preferred shares, no par value; nil and 3,901,348 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively$7,874
Shareholders’ equity:
Ordinary shares, no par value; 193,277,622 and 187,660,263 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively$1,627,209$1,616,478

Item 1. Financial Statements

FAQ

What is Wave Life Sciences's total non-current liabilities?
Wave Life Sciences (WVE) reported total non-current liabilities of $53.99M in Q2 2026.
How has Wave Life Sciences's total non-current liabilities changed year-over-year?
Wave Life Sciences's total non-current liabilities increased by 203.2% year-over-year, from $17.81M to $53.99M.
What is the long-term trend for Wave Life Sciences's total non-current liabilities?
Over 5 years (2020 to 2025), Wave Life Sciences's total non-current liabilities has grown at a -23.9% compound annual growth rate (CAGR), from $67.55M to $17.2M.
What does total non-current liabilities mean?
The sum of all long-term obligations due beyond one year — long-term debt, lease liabilities, pension obligations, and deferred items.

Ask your AI about Wave Life Sciences's total non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude